NCT04152226View on ClinicalTrials.gov

A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis

PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions

Tinea Pedis

Interventions

DRUG

Janthinobacterium lividum

Investigational Product

Trial Locations (1)

Unknown

Instituto Dermatologico y Cirugia de Piel, Santo Domingo

Sponsors

Lead Sponsor

DermBiont, Inc.

All Listed Sponsors

lead

DermBiont, Inc.

INDUSTRY

NCT04152226 - A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis | Biotech Hunter | Biotech Hunter